Yotai Refractories Co., Ltd. (JP:5357) has released an update. Yotai Refractories Co., Ltd. has announced its decision to ...

Please find enclosed herewith extract of statement of Unaudited Consolidated Financial Results for the quarter and six months 30th September, 2024 published in newspapers, Business Standard -All ...

NILACHAL REFRACTORIES LTD. - Board Meeting Intimation for Board Meeting Is Scheduled To Declared 2Nd Quarter For Financial 2024-25.

HarbisonWalker International is investing $13.9 million in Fulton, creating 11 new jobs with a modern facility expanding ...

Currently Corvus is enrolling patients in a registrational Phase 3 trial to evaluate soquelitinib to treat refractory ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Eric Easom, the company's co-founder, chairman, president and chief executive officer, said recent data analysis indicate that epetraborole may provide clinical improvement in patients with ...